Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Boggild

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
BMJ Open|January 21, 2014
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov modelJacqueline Palace, Thomas Bregenzer, Helen Tremlett, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 31, 2010
The Multiple Sclerosis Severity Score: associations with MC1R single nucleotide polymorphisms and host response to ultraviolet radiationRichard C Strange, Sudarshan Ramachandran, Maurice P Zeegers, et al.
Multiple Sclerosis and Related Disorders|July 13, 2023
Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022Steve Simpson-Yap, Duncan Maddox, Jeanette Reece, et al.
Clinical Immunology (Orlando, Fla.)|June 18, 2013
Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complementSwaminathan Sethu, Karthik Govindappa, Paul Quinn, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 12, 2012
Adult-onset spinocerebellar ataxia syndromes due to MTATP6 mutationsGerald Pfeffer, Emma L Blakely, Charlotte L Alston, et al.
Multiple Sclerosis and Related Disorders|August 4, 2024
Longitudinal epidemiology of multiple sclerosis over 60 years in Newcastle, Australia: 1961 to 2021Steve Simpson-Yap, Vicki E Maltby, Stacey Hall, et al.
BMC Neurology|January 8, 2009
The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the futureMark Pickin, Cindy L Cooper, Timothy Chater, et al.
The Lancet. Neurology|April 6, 2015
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparatorJacqueline Palace, Martin Duddy, Thomas Bregenzer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing schemeJacqueline Palace, Martin Duddy, Michael Lawton, et al.
Archives of Neurology|September 10, 2008
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patientsAnu Jacob, Brian G Weinshenker, Ivo Violich, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
BMJ Open|January 21, 2014
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov modelJacqueline Palace, Thomas Bregenzer, Helen Tremlett, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 31, 2010
The Multiple Sclerosis Severity Score: associations with MC1R single nucleotide polymorphisms and host response to ultraviolet radiationRichard C Strange, Sudarshan Ramachandran, Maurice P Zeegers, et al.
Multiple Sclerosis and Related Disorders|July 13, 2023
Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022Steve Simpson-Yap, Duncan Maddox, Jeanette Reece, et al.
Clinical Immunology (Orlando, Fla.)|June 18, 2013
Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complementSwaminathan Sethu, Karthik Govindappa, Paul Quinn, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 12, 2012
Adult-onset spinocerebellar ataxia syndromes due to MTATP6 mutationsGerald Pfeffer, Emma L Blakely, Charlotte L Alston, et al.
Multiple Sclerosis and Related Disorders|August 4, 2024
Longitudinal epidemiology of multiple sclerosis over 60 years in Newcastle, Australia: 1961 to 2021Steve Simpson-Yap, Vicki E Maltby, Stacey Hall, et al.
BMC Neurology|January 8, 2009
The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the futureMark Pickin, Cindy L Cooper, Timothy Chater, et al.
The Lancet. Neurology|April 6, 2015
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparatorJacqueline Palace, Martin Duddy, Thomas Bregenzer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing schemeJacqueline Palace, Martin Duddy, Michael Lawton, et al.
Archives of Neurology|September 10, 2008
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patientsAnu Jacob, Brian G Weinshenker, Ivo Violich, et al.
Pageof 6